Delving into the Latest Updates on MVA Mosaic HIV vaccine (Janssen Vaccines and Prevention) with Synapse

Overview

Basic Info

Drug Type

Prophylactic vaccine

Synonyms

MVA HIV vaccineJanssen Vaccines and Prevention, MVA mosaicJanssen Vaccines and Prevention, Modified Vaccinia Ankara Mosaic HIV vaccine Janssen Vaccines and Prevention

+ [1]

Target-

Action

stimulants

Mechanism

Immunostimulants

Therapeutic Areas

Immune System DiseasesInfectious DiseasesUrogenital Diseases

Active Indication-

Inactive Indication

HIV Infections

Originator Organization

Crucell NV

Active Organization-

Inactive Organization

Janssen Vaccines & Prevention BV

Beth Israel Deaconess Medical Center, Inc.

License Organization-

Drug Highest PhasePendingPhase 1/2

First Approval Date-

Regulation-

Login to view timeline

The primary purpose of this study is to assess safety/tolerability of 2 different prime/boost regimens containing adenovirus serotype 26 (Ad26).Mos4.HIV, Modified Vaccinia Ankara (MVA) -Mosaic or adjuvanted Mosaic and Clade C gp140 in Human immunodeficiency virus type 1 (HIV-1)-infected participants on suppressive antiretroviral treatment (ART).

Start Date05 Mar 2018

Sponsor / Collaborator

Janssen Vaccines & Prevention BV

[+2]

NCT02919306

/ CompletedPhase 1/2

A Combined Phase 1/2a, Exploratory Study of a Therapeutic Vaccine Using an Adenovirus Type 26 Vector Prime and Modified Vaccinia Ankara Boost Combination With Mosaic Inserts in HIV-1 Infected Adults Who Initiated Antiretroviral Treatment During Acute HIV Infection

The purpose of the study is to assess: 1 safety and tolerability of adenovirus serotype 26 (Ad26) prime and Modified Vaccinia Ankara (MVA) boost versus placebo in participants on suppressive antiretroviral therapy (ART) that was initiated during acute Human Immunodeficiency Virus (HIV) infection; 2) Measure the frequency and duration of sustained viremic control after receiving Ad26 prime/MVA boost or placebo, defined as greater than 24 weeks with plasma HIV ribonucleic acid (RNA) lesser than (<)50 copies/ml after antiretroviral (ARV) analytical treatment interruption (ATI).

Start Date01 Sep 2016

Sponsor / Collaborator

Janssen Vaccines & Prevention BV

NCT02315703

/ CompletedPhase 1/2

A Phase 1/2a Trial to Evaluate the Safety/Tolerability and Immunogenicity of Homologous Ad26 Mosaic Vector Regimens or Ad26 Mosaic and MVA Mosaic Heterologous Vector Regimens, With High-Dose, Low-Dose or no Clade C gp140 Protein Plus Adjuvant for HIV Prevention

The purpose of this study is to assess the safety and tolerability of various regimens containing adenovirus serotype 26-Mosaic -Human Immunodeficiency Virus (Ad26.Mos.HIV), Modified Vaccinia Ankara (MVA)-Mosaic, and/or HIV type 1 Clade C glycoprotein 140 drug product (gp140 DP) components and to compare envelope binding antibody responses between the different vaccine regimens.

Start Date22 Dec 2014

Sponsor / Collaborator

Janssen Vaccines & Prevention BV

[+3]

100 Clinical Results associated with MVA Mosaic HIV vaccine (Janssen Vaccines and Prevention)

Login to view more data

100 Translational Medicine associated with MVA Mosaic HIV vaccine (Janssen Vaccines and Prevention)

Login to view more data

100 Patents (Medical) associated with MVA Mosaic HIV vaccine (Janssen Vaccines and Prevention)

Login to view more data

100 Deals associated with MVA Mosaic HIV vaccine (Janssen Vaccines and Prevention)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
HIV Infections	Phase 2	United States	Janssen Vaccines & Prevention BV	22 Dec 2014
HIV Infections	Phase 2	Thailand	Janssen Vaccines & Prevention BV	22 Dec 2014
HIV Infections	Phase 2	South Africa	Janssen Vaccines & Prevention BV	22 Dec 2014
HIV Infections	Phase 2	Rwanda	Janssen Vaccines & Prevention BV	22 Dec 2014
HIV Infections	Phase 2	Uganda	Janssen Vaccines & Prevention BV	22 Dec 2014

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02919306 (CTgov)	Phase 1/2	HIV Infections	27	MVA-Mosaic+Ad26.Mos.HIV (Ad26.Mos.HIV Vaccine or MVA Mosaic Vaccine)	xmmknzxrez(rvzttebqwc) = frumgbguol mabpwgipgp (sojuawlurt, kxxjufarae - vxkwecmbbn) View more	-	11 Mar 2022
				Placebo (Placebo)	xmmknzxrez(rvzttebqwc) = drsplgecjs mabpwgipgp (sojuawlurt, zpximalwzo - lskalxuopo) View more